ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Dow To Move Pennsylvania Researchers To New Labs

Research: Dow says move will substantially increase lab and pilot-plant space

by Alexander H. Tullo
July 9, 2012 | APPEARED IN VOLUME 90, ISSUE 28

Dow Chemical has agreed to lease a College­ville, Pa., R&D facility owned, and once operated, by Pfizer. Some 800 researchers will begin the move from Dow’s current site in Spring House, Pa., in the first quarter of 2013. The labs are about 17 miles apart in Montgomery County.

Pfizer ended research operations at Collegeville in 2010 as part of an R&D consolidation after its 2009 purchase of Wyeth. That year, the company laid off 450 workers in Collegeville, although the firm’s specialty care unit is still based there.

Dow, meanwhile, acquired the Spring House facility in 2009 when it purchased Rohm and Haas, which had opened the labs in 1963. Since the acquisition, the facility has started to support Dow businesses such as performance plastics and Dow AgroSciences.

Dow says the 750,000-sq-ft College­ville facility offers a substantial increase in lab and pilot-plant space that can better accommodate future growth in research operations. “Dow did a comprehensive feasibility study and found it would be cost-prohibitive to upgrade the Spring House facility rather than customize Collegeville,” a Dow spokeswoman tells C&EN.

Jerome A. Peribere, president of Dow Advanced Materials, points out that Dow can now expand R&D close to the Philadelphia headquarters of his business unit. “This strategy bolsters our company’s long-standing commitment to Pennsylvania by putting R&D operations on a long-term path forward,” he says.

The Collegeville site isn’t the first Pfizer facility to be repurposed by another firm. In 2010, Monsanto purchased Pfizer’s 1.5 million-sq-ft research facility in Chesterfield, Mo., for $435 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment